Nasdaq: #IRD
Opus Genetics and the Global RDH12 Alliance are teaming up to accelerate development of a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare and severe form of childhood blindness.
#OpusGenetics
prismmarketview.com/opus-genetic...

Big news in eye care! Opus Genetics’ (Nasdaq: #IRD) presbyopia treatment met key goals in its Phase 3 trial, showing rapid and lasting improvement in near vision. FDA submission coming later this year.
#OpusGenetics
prismmarketview.com/opus-genetic...

Close-up of a human eye with a digitally superimposed dollar sign reflecting in the iris, symbolizing investment in vision research by Opus Genetics.

Here’s looking at you investors!! Opus Genetics (Nasdaq: #IRD) secures up to $2M in non-dilutive funding to advance its gene therapy for MERTK-related retinitis pigmentosa—an inherited eye disease with no approved treatments.
#OpusGenetics
prismmarketview.com/opus-genetic...

#OpusGenetics Nasdaq: #IRD is leading the PRISM Emerging Pharmaceutical Index, up 19% on Positive Phase 3 Results for Night Vision Therapy.
Learn more about Opus here: bit.ly/3SuIlkT

PRISM Mid-Day Movers:
#AppliedDigital ( #APLD) soars 49% on a massive $7B, 15-year AI lease deal, boosting the AI Datacenter Index.
#OpusGenetics ( #IRD) up 25% after hitting the mark in its Phase 3 trial for visual disturbances—big news for LASIK patients!
prismmarketview.com/prism-mid-da...

Opus Genetics Surges 32% Premarket on Positive Phase 3 Results for Night Vision Therapy Opus Genetics, Inc. (Nasdaq: IRD) today announced that its Phase 3 LYNX-2 trial met the primary endpoint for Phentolamine Ophthalmic Solution 0.75%, demonstrati

#OpusGenetics #IRD jumped 32% premarket after reporting positive Phase 3 results for Phentolamine 0.75%, meeting the primary endpoint in patients with night vision issues following LASIK and related procedures. prismmarketview.com/opus-genetic...